The service comprises initially 76 genes related to 18 diseases such as tumors, cardiomyopathy, congenital hearing loss, and immune disorders. Among these genes are APC, BRCA1 / 2, RET, SMAD4, TP53 and other genes familiar in cancer medicine, as well as the KCNH2 gene for hereditary arrhythmia / congenital long QT syndrome and the TTR gene for familial amyloidosis. , CYP2C9 gene related to drug metabolism, etc.. Once the test is on track, it is planned to expand to 193 genes and chromosomal structural abnormalities.

Phase 1 is a practical study (feasibility study). Phase 2 starting in July will comprise about 100 people at a cost of 400,000 yen per person. Phase 3, which is scheduled to start in January 2022, will upgrade to the hospital business, and plans for about 1000 people. At this stage, the cost per subject is assumed to be 500,000 to 650,000 yen.

Nikkei Biotech news release, June 24, 2021